Prospective registry study for children and young adults with severe immune cytopenias (persisting/chronic immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome) to improve the management, facilitate the differential diagnostic work-up, and document the clinical course under various treatments. Time points: at inclusion, after 6 months, after 12 months, then yearly up to 4 years after inclusion. No intervention, mere observation and documentation. Guided pre-inclusion (differential) diagnostic work-up.
The study aims to improve the management and care of patients with severe immune cytopenias, to identify underlying causes of severe immune cytopenias and to develop a strategy for early treatment stratification based on a standardized diagnostic algorithm, potentially supported by biomarker analyses and (off study) genetic analyses, where clinically indicated. Primary Goal: Rapid detection of underlying causes of severe immune cytopenias with the aid of a structured diagnostic approach and access to a clinical care network of the participating centers, allowing early treatment stratification Secondary Goals: * Collection of data about epidemiology of rare diseases * Systemic documentation of response rates to various treatments * Identification of biomarkers and modifiers of immune tolerance * Collection of data about the usage of novel/experimental therapeutic agents * Documentation of physician-reported outcome measures/performance scores * Consultation of the caring physicians through a regular SIC-Reg board There will be no additional venous punctures or investigational time points. At clinical visits around planned study time points, additional blood parameters and stool specimen will be obtained. The current clinical management follows international guidelines, which are summarized in the study documents but do not represent part of the study (no diagnostic or therapeutic investigational arm).
Study Type
OBSERVATIONAL
Enrollment
80
facs analysis, microbiome analysis
Pediatric Hematology-Oncology Outpatient Clinic
Graz, Styria, Austria
underlying disease that causes or is associated with severe immune cytopenia
identify the underlying condition or other disease, e.g., primary immunodeficiency or bone marrow failure syndrome by diagnostic procedures according to a standardized algorithm
Time frame: 0-4 years
Clinical course
Documentation of physician-reported clinical symptoms including outcome measures/performance scores
Time frame: 0-4 years
Biomarkers - Blood
Identification of novel biomarkers by flow cytometry of leukocytes
Time frame: 0-4 years
Biomarkers - Stool
Identification of potential modifiers of immune tolerance by studying the intestinal microbiome
Time frame: 0-4 years
Routine laboratory parameters
documentation of laboratory parameters that are routinely assessed for immune cytopenia
Time frame: 0-4 years
Number of participants with the diagnosis of severe immune cytopenia per participating centre and per year
epidemiological data acquisition, participants included according to the inclusion criteria
Time frame: 0-4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.